z-logo
Premium
Long‐term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?
Author(s) -
Boer J.,
Nazary M.
Publication year - 2011
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2010.10071.x
Subject(s) - misnomer , acitretin , hidradenitis suppurativa , dermatology , medicine , acne , isotretinoin , term (time) , psoriasis , disease , philosophy , physics , theology , quantum mechanics
Summary Background  Hidradenitis suppurativa (HS) is a distressing chronic inflammatory skin disorder which affects predominantly the groins and axillae. In analogy to acne, oral isotretinoin has been considered in the treatment of HS, although there are strong indications that this drug has only a very limited therapeutic effect. During the past 25 years scattered case reports have described promising results of treatment with acitretin. Objectives  To evaluate the long‐term efficacy of acitretin monotherapy. Methods  A retrospective study in 12 patients with severe, recalcitrant HS who were treated with acitretin for 9–12 months at one Dermatology Centre in the Netherlands between 2005 and 2007 and were followed up to 4 years. The patients were men and infertile women. The efficacy of the treatment was rated by the patients on global maximum pain of nodules and abscesses on a visual analogue scale (VAS) as well as by physician global assessment. Results  All 12 patients achieved remission and experienced a significant decrease in pain as assessed by VAS. In nine patients long‐lasting improvement was observed, with no recurrence of lesions after 6 months ( n  =   1), 1 year ( n  =   3), > 2 years ( n  =   2), > 3 years ( n  =   2) and > 4 years ( n  =   1). Conclusions  Acitretin appears to be an effective treatment for refractory HS, leading to reduction of pain from painful nodules and reducing the extent of the disease for a prolonged period.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here